Holen Sie sich die Stockscreener-App
37.77
5.57%
-2.23
Handel nachbörslich:
37.77
Schlusskurs vom Vortag:
$40.00
Offen:
$39.94
24-Stunden-Volumen:
2.74M
Relative Volume:
0.72
Marktkapitalisierung:
$4.11B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-95.90M
KGV:
-28.61
EPS:
-1.32
Netto-Cashflow:
$-79.09M
1W Leistung:
-6.51%
1M Leistung:
-6.11%
6M Leistung:
+733.77%
1J Leistung:
+620.11%
1-Tages-Spanne:
$37.17
$40.39
1-Wochen-Bereich:
$37.17
$41.26
52-Wochen-Spanne:
$1.865
$48.26
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Firmenname
Terns Pharmaceuticals Inc
Sektor
Branche
Telefon
650-525-5535 EXT.101
Adresse
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Vergleichen Sie TERN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
37.77 | 4.35B | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-11-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-10-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-06-22 | Eingeleitet | Mizuho | Buy |
| 2023-06-07 | Eingeleitet | Jefferies | Buy |
| 2023-05-31 | Eingeleitet | ROTH MKM | Buy |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-02-07 | Eingeleitet | UBS | Buy |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-09-14 | Fortgesetzt | Goldman | Buy |
| 2021-03-02 | Eingeleitet | Cowen | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Buy |
| 2021-03-02 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Terns Pharmaceuticals Inc Aktie (TERN) Neueste Nachrichten
Terns Pharmaceuticals (TERN) price target increased by 75.91% to 54.63 - MSN
Why Terns Pharmaceuticals Inc. stock could see breakout soonEarnings Beat & Consistent Return Investment Signals - ulpravda.ru
Why Terns Pharmaceuticals Inc. stock could be next big winnerEarnings Recap Summary & Daily Entry Point Trade Alerts - ulpravda.ru
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Daily News - FinancialContent
Terns Pharmaceuticals CMO Kuriakose sells $44,552 in stock - Investing.com
Terns Pharmaceuticals CEO Burroughs sells $2.7m in shares By Investing.com - Investing.com Nigeria
Terns Pharmaceuticals CEO Burroughs sells $2.7m in shares - Investing.com
With 53% Institutional Ownership, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Is a Favorite Amongst the Big Guns - 富途牛牛
Terns Pharmaceuticals reports inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Terns Pharmaceuticals Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Tern Pharmaceuticals (TERN) Soars 630% on CML Treatment Best-in-Class Potential - Insider Monkey
Meet the 10 Market Stars Behind Millionaire-Making in 2025 - Insider Monkey
Terns Pharmaceuticals Earnings Notes - Trefis
The biggest end-of-year sale in the Bay Area was for $4 billion in biotech stockSan Francisco Business Times - The Business Journals
12 Overlooked Stocks That Delivered Massive Gains In 2025 - RTTNews
Terns Pharmaceuticals stock slides today, testing the $40 level after December share sale - ts2.tech
Terns Pharmaceuticals stock soars after leukemia drug delivers big early responses in tough-to-treat patients - MSN
Pharmaceutical Stocks To Follow TodayDecember 10th - MarketBeat
Terns Pharmaceuticals proposes $400M equity offering - MSN
Terns Pharmaceuticals (TERN) climbs 53% on stellar leukemia treatment trial - MSN
Truist Securities maintains Terns Pharmaceuticals (TERN) buy recommendation - MSN
Terns Pharmaceuticals (TERN) Is Down 7.7% After Strong TERN-701 Phase 1 DataHas The Bull Case Changed? - Sahm
Jim Cramer highlights massive gains for Terns Pharmaceuticals shareholders - MSN
Terns Pharmaceuticals (TERN) Price Target Increased by 75.91% to 54.63 - Nasdaq
Will Terns Pharmaceuticals Inc. stock gain from government policies2025 Bull vs Bear & Weekly High Potential Alerts - moha.gov.vn
How Terns Pharmaceuticals Inc. stock performs in weak economyEarnings Performance Report & High Conviction Trade Alerts - Улправда
Is Terns Pharmaceuticals Inc. stock attractive for long term wealth buildingJobs Report & Target Return Focused Stock Picks - Улправда
Jim Cramer Highlights Massive Gains for Terns Pharmaceuticals Shareholders - Finviz
Terns Pharmaceuticals unveils promising phase 1 trial data - MSN
Insider Trends: How Terns Pharmaceuticals Inc. stock performs in weak economyJuly 2025 Volume & Free Expert Approved Momentum Trade Ideas - Улправда
Is Terns Pharmaceuticals Inc. stock a contrarian buy2025 Price Momentum & Free High Accuracy Swing Entry Alerts - Улправда
Terns Pharmaceuticals (TERN) Stock Today (Dec. 18, 2025): Why Shares Are Sliding After the Rally, and What Analysts Forecast Next - ts2.tech
Jim Cramer Was Asked About These 11 Stocks - Insider Monkey
Operating cash flow per share of Terns Pharmaceuticals, Inc. – GETTEX:430 - TradingView — Track All Markets
Terns Pharmaceuticals (TERN) Stock Today: Latest News, Analyst Forecasts, and What to Watch (December 16, 2025) - ts2.tech
Terns Pharmaceuticals (TERN): Valuation Check After Strong CARDINAL Trial Data for CML Candidate TERN-701 - simplywall.st
Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid LeukemiaSlideshow (NASDAQ:TERN) 2025-12-15 - Seeking Alpha
Terns CEO Amy Burroughs talks cancer drug trial win - CNBC
Biotech ETF SBIO Hovers Near Peak on Rally - ETF Database
Terns Pharmaceuticals raises $747.5 million in upsized offering - Traders Union
Terns Pharmaceuticals (TERN) Climbs 53% on Stellar Leukemia Treatment Trial - Finviz
10 Stocks Delivering Explosive 18-190% Gains - Insider Monkey
Finanzdaten der Terns Pharmaceuticals Inc-Aktie (TERN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):